Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Novartis, Conatus Lands Experienced, Deep-Pocketed NASH Partner

Executive Summary

Biotech gets $50m up front, up to $650m in milestones, significant royalties and the option to co-promote emricasan in NASH in the US. Novartis also may combine the caspase inhibitor with its Phase II FXR agonist.


Related Content

Conatus Endures Another NASH Setback With Failure To Hit Fibrosis Endpoint
In NASH Race, Bad News For Conatus, Good News For Genfit In PBC
Pfizer/Novartis Collaboration Brings Combined Strength To NASH Development
Deal Watch: Seattle Genetics' Controversial Collaboration With Immunomedics Topples
Could High Profile Combo Be Allergan/Novartis Answer To Late-Stage NASH Programs?
Madrigal Believes It Holds The Key To NASH: Clearing The Fat
Combination Strategies A Common Thread In NASH R&D
Endpoint Selection Could Help Determine The NASH Race
The NASH Pipeline: Replete With Targets And New Compounds
Conatus' Liver Focus Goes Well Beyond NASH


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts